About Us
About New York Cryogen
New York Cryogen, Inc. is developing the AC-130 Viper. The company’s current focus is product engineering, testing, quality preparation, and regulatory work.
Gregory Papageorge, the CEO & Founder of New York Cryogen Inc., possesses a deep understanding of chronic pain, not just professionally, but personally. His journey in the medical field began as a complex spine sales representative, where he provided clinical support and assisted orchestrate the use of his deformity spine systems for neurosurgeons and orthopedic spine surgeons participating in numerous operations assuring the surgical systems were being used correctly.
The Challenge & Breakthrough
The company was founded by Gregory Papageorge. His experience in medical technology and his personal experience with chronic pain motivated the exploration of localized cooling technology and the development program that became the AC-130 Viper
The AC-130 Viper remains under development. New York Cryogen is working toward a controlled product configuration and the documentation needed to support regulatory review and future manufacturing readiness.
Regulatory Status
FDA 510(k) clearance for the AC-130 Viper is pending.
The company will update this website when the product’s regulatory status changes.
Join the Pain Relief Revolution
The AC-130 VIPER is set for distribution in Spring 2024. Healthcare professionals passionate about cutting edge pain relief solutions are encouraged to connect with us.